Bausch Health Cos (NYSE:BHC) Director Frank Lee Sells 24,456 Shares

Bausch Health Cos Inc. (NYSE:BHC) Director Frank Lee sold 24,456 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the transaction, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Price Performance

Shares of NYSE BHC traded up $0.19 during midday trading on Wednesday, hitting $5.51. 1,876,907 shares of the company’s stock were exchanged, compared to its average volume of 1,978,303. Bausch Health Cos Inc. has a 12-month low of $4.41 and a 12-month high of $8.69. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -1.70 and a beta of 0.42. The business’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $6.14.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.37 billion. As a group, research analysts forecast that Bausch Health Cos Inc. will post 4.08 EPS for the current fiscal year.

Bausch Health Cos News Summary

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Shareholders approved all 10 director nominees at Bausch Health’s 2026 Annual Meeting, including the election of new director Dr. Eiry W. Roberts, which signals continuity in governance and adds a director with pharma and clinical development experience. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate slightly for Bausch Health, reflecting a modest improvement in expected full-year profitability.
• Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and Barclays Leveraged Finance Conference; these events can give management a chance to reinforce its strategy, but the transcripts did not include a clear new catalyst in the supplied headlines. Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
• Negative Sentiment: Zacks Research cut several out-year earnings estimates, including FY2027, FY2028, and specific 2027–2028 quarterly forecasts, which may raise concerns about longer-term growth and margin expectations.

Institutional Trading of Bausch Health Cos

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Paulson & CO. Inc. lifted its position in Bausch Health Cos by 3.5% in the fourth quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after purchasing an additional 2,500,000 shares during the last quarter. Goldentree Asset Management LP lifted its position in Bausch Health Cos by 1.7% in the third quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after purchasing an additional 578,542 shares during the last quarter. Vanguard Group Inc. lifted its position in Bausch Health Cos by 4.0% in the third quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after purchasing an additional 470,968 shares during the last quarter. Royal Bank of Canada lifted its position in Bausch Health Cos by 24.9% in the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after purchasing an additional 2,262,894 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Bausch Health Cos by 65.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after purchasing an additional 2,038,813 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BHC shares. Barclays dropped their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Royal Bank Of Canada dropped their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Finally, Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $8.00.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.